KRAS / RAS targeting: from platform to Phase 3
Chinese groups are not short of G12C molecules (elisrasib’s floor numbers are strong).
Breaking news from AACR: Single-agent administration of the KRAS G12C inhibitor elisrasib demonstrated tolerability and promising antitumor activity in a phase 1/2 trial in previously treated KRAS G12C mutation-positive non-small cell #lung cancer. Antitumor effects were also
Heat 12 · 11 likes · 0 replies · 1 repost
Kanwal Pratap Raghav, Jun Zhang, Myung-Ah Lee, Jingdong Zhang, John Park, Yanqiao Zhang, Susana Rosello Keranen, Byoung Chul Cho, Herbert Ho Fung Loong, Cheng Chen, Huan Li, Shaonan Wang, Yandong Shen, Zifei Fan, Qian Chen, Hui Wang, Jing Zhang, George Zhi Jian Chen, Jayesh Desai, Antoine Hollebecque
Read the abstract →Source: cancer_navi · x.com